Dual Layered for Dual Protection in Carotid PCI

At present, there is more than one dual layered stent in the market offering additional protection in carotid PCI. Therefore we saw fit to look at these devices to compare class benefits and find any specific differences. 

Doble mallado para doble protección en angioplastia carotídea

This study assessed the safety and efficacy of two dual layered mesh covered stents especially designed for carotid PCI. These had been already assessed separately and in small studies: the Roadsaver de Terumo and the CGuard de InspireMD.

A meta-analysis was carried out of studies that had included over 100 cases. Primary end point was death or stroke rate. Secondary end points included restenosis and thrombosis. 

Patients were divided in two groups according to device: Roadsaver (n=250) and CGuard (n=306).

Mortality rate at one-year followup for Terumo was 2.8%, while CGuard obtained 1.31%, a non-significant difference.

Something similar happened with stroke (1.6% vs 1.9%, respectively).


Read also: Number of Hours of Sleep and Risk of Stroke.


A clinical indication of carotid PCI was the only predictor of death or stroke.

The only significant difference was restenosis, with 4% for Roadsaver and 0.65% for CGuard (p=0.007). One patient in each group developed stent thrombosis. 

The use of Terumo was the sole predictor of restenosis.

Conclusion

With an extremely low annual rate of stroke for both devices, it seems dual layered mesh covered stents are taking hold of carotid PCI. Restenosis rate in one of the devices resulted superior to its competitor’s, though still within a low rate. 

Original Title: Use of Dual-Layered Stents for Carotid Artery Angioplasty. 1-Year Results of a Patient-Based Meta-Analysis.

Reference: Eugenio Stabile et al. J Am Coll Cardiol Intv 2020;13:1709–15.https://doi.org/10.1016/j.jcin.2020.03.048.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...